Published: May 18, 2021 By Alex Keown
Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Hummingbird Bioscience Raises $125 Million
Singapore-based
raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research.
Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors.
The funds will also be used to expand the capabilities of Hummingbird s proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics, including HMBD-009, a BCMA-TACI dual-specific T cell engager.
Hummingbird Bioscience buzzes with $150M series C led by Novo Holdings fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Search jobs 15-Apr-2021 HUMMINGBIRD BIOSCIENCE PRESENTS PRE-CLINICAL DATA ON ITS NEXT-GENERATION BCMA-TACI DUAL-SPECIFIC T CELL ENGAGER AT 2021 AACR ANNUAL MEETING
HUMMINGBIRD BIOSCIENCE
2021 AACR ANNUAL MEETING
Singapore, April 10, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
HMBD-009 is Hummingbird’s next-generation T cell program that uniquely targets both B cell maturation antigen (BCMA) and Transmembrane activator and CAML Interactor (TACI), proteins commonly overexpressed in multiple myeloma, the second most common hematologic malignancy and a leading cause
Share this article
Share this article
SINGAPORE, Dec. 14, 2020 /PRNewswire/ Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. As part of the collaboration, Hummingbird will be leveraging Tempus AI-enabled platform and proprietary data, as well as joining its TIME Trial® Network, for rapid identification, site activation and efficient enrollment of cancer patients who have NRG1 fusions and meet eligibility criteria for HMBD-001 clinical trials.